Regulator
Medtronic said the FDA cleared Hugo for general surgery, including gallbladder removal and hernia repair.
A regulator's decision · Company-reported · Sets Hugo's stage
What the source says
“Medtronic said Tuesday the Food and Drug Administration has cleared the Hugo robotic system for use in general surgery procedures.”
What it means
Medtronic's claim, if it holds, widens what Hugo can do in the US well beyond urology. It follows the June 2026 request to the FDA for general surgery and gynecologic surgery. The record shows nothing yet on the gynecologic request. Hugo has been at stage 5 since its first US urology clearance, and the first US operation came in February 2026. Rivals such as da Vinci 5 and Dexter also sit at stage 5, so the contest now looks like one of range of uses.
Hugo, from Medtronic, is at stage 5 of 5 on our ladder: regulator-cleared or mass market. This event is one of the milestones that placed it there. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: The maker hasn't said whether people help it remotely.
Written with AI from our record of Hugo and checked against it: every figure appears in that record.
More on Hugo
- The FDA cleared a Medtronic vessel-sealing instrument for use with Hugo. Medtronic expects Hugo to pass 50,000 completed operations this financial year.
- Medtronic agreed to sell Cornerstone Robotics' Sentire surgical robot alongside Hugo in some markets outside the US, as part of a deal of about $700 million.
- Medtronic asked the FDA to clear Hugo for general surgery, including hernia repair, and for gynecologic surgery.
- The first US operation with Hugo, a prostate removal, was done at Cleveland Clinic in February 2026.
- The FDA cleared Hugo for soft-tissue urology operations, such as on the prostate, kidney and bladder.
- Medtronic executives said supply chain and manufacturing problems slowed Hugo's rollout after the pandemic.
